eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
1/2024
vol. 11
 
Share:
Share:
abstract:
Case report

Evolocumab-induced delayed skin hypersensitivity reaction in a patient with familial hypercholesterolaemia

Grzegorz Porebski
1
,
Alicja Dziadowiec
1, 2

  1. Department of Clinical and Environmental Allergology, Jagiellonian University, Medical College, Krakow, Poland
  2. Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
Alergologia Polska – Polish Journal of Allergology 2024; 11, 1: 73–75
Online publish date: 2024/02/20
View full text Get citation
 
PlumX metrics:
In this report, we describe a patient with a delayed cutaneous hypersensitivity reaction to evolocumab, a human monoclonal antibody directed against the serine protease proprotein convertase subtilisin/kexin type 9 used to reduce low-density lipoprotein concentrations in the treatment of familial hypercholesterolaemia. The patient developed erythematous exfoliative lesions on the skin after the third administration of evolocumab. After each of the next three consecutive doses, the lesions worsened for 24 h, persisted for approximately 7 days, and then went into partial remission. Discontinuation of evolocumab resulted in a complete remission. Hypersensitivity reactions induced by biological drugs are becoming an increasing problem, but knowledge of these reactions is still limited. Our case report convincingly demonstrates the causal relationship between repeated drug exposure and the development and exacerbation of clinical symptoms. It also highlights a dilemma in the management of such clinical situations: the ‘treat-through’ strategy versus withdrawal of vital treatment.
keywords:

allergy, familial hypercholesterolaemia, drug hypersensitivity reactions, evolocumab, rash



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.